GlassScriptPhysician profile
Ferdinand C Martinez
NPI 1194911107
$4,126.62
in general payments reported to CMS, 2019-2025
29 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,909 · 2020: $164 · 2021: $313 · 2022: $165 · 2023: $445 · 2024: $485 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,446.07 | 2019 | |
| Organogenesis INC. | $701.36 | 2021-2025 | Puraply, Affinity, Puraply Wound Matrix |
| Medtronic Vascular, INC. | $316.54 | 2019 | |
| Smith+Nephew, INC. | $266.46 | 2019-2025 | Collagenase Santyl, Regranex, Renasys Go V2 Home |
| Cumberland Pharmaceuticals, INC. | $160.05 | 2019-2025 | Vibativ |
| Tactile Systems Technology INC | $114.11 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Kerecis Limited | $105.49 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Reprise Biomedical, INC. | $98.91 | 2024-2025 | Miro3d |
| Paratek Pharmaceuticals, INC. | $94.05 | 2020-2025 | Nuzyra |
| Lifenet Health | $91.25 | 2023-2024 | Theragenesis Wound Matrix |
| Merck Sharp & Dohme LLC | $86.98 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Kci USA, INC. | $86.68 | 2019-2020 | |
| Misonix INC | $74.78 | 2021 | |
| Shionogi INC | $64.18 | 2021-2024 | Fetroja |
| Bioventus LLC | $62.18 | 2022-2023 | Sonicone Clinic |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $60.48 | 2023-2024 | |
| Abbvie INC. | $42.43 | 2021 | |
| Ferring Pharmaceuticals INC. | $40.85 | 2023-2025 | Rebyota |
| Hartmann USA, INC. | $39.70 | 2021-2022 | |
| Boston Scientific Corporation | $30.77 | 2023 | Varithena Administration Pack |
| Grt US Holding, INC. | $28.36 | 2022 | |
| Baudax Bio INC. | $19.36 | 2020 | |
| Angiodynamics, INC. | $19.32 | 2020 | |
| Gilead Sciences, INC. | $15.66 | 2024 | Veklury |
| Aroa Biosurgery Incorporated | $13.33 | 2019 | |
| Astellas Pharma US INC | $12.74 | 2020 | |
| Janssen Biotech, INC. | $12.59 | 2019 | |
| Mckesson Patient Care Solutions INC. | $11.06 | 2019 | |
| Molnlycke Health Care US, LLC | $10.88 | 2023 | Exufiber Ag+, Mepilex Border Flex, Mepilex Transfer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdinand Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.